{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:49:20Z","timestamp":1764996560374},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152515","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:02:41Z","timestamp":1721088161000},"page":"152515","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged \u226565 years"],"prefix":"10.1016","volume":"68","author":[{"given":"Chengchen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Amill-Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abree","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haeyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O'Mareen","family":"Spence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Driss","family":"Oraichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Franck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"dosReis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152515_bib0001","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.idc.2017.07.016","article-title":"Herpes zoster in the older adult","volume":"31","author":"John","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0004","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk Factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0005","unstructured":"European Medicines Agency. Shingrix. Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf; 2022 [accessed August 30, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0006","unstructured":"U.S. Food and Drug Administration. Shingrix (zoster vaccine recombinant, adjuvanted), suspension for intramuscular injection. Highlights of Prescribing Information, https:\/\/www.fda.gov\/media\/108597\/download?attachment; 2023 [accessed August 30, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0007","unstructured":"Fink DL (U.S. Food and Drug Administration). Supplement Approval (BL 125614\/398), https:\/\/www.fda.gov\/media\/151063\/download?attachment; 2021 [accessed January 7, 2024]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0009","unstructured":"U.S. Food and Drug Administration. Shingrix (zoster vaccine recombinant, adjuvanted). Vaccines and Related Biological Products Advisory Committee. FDA briefing document, https:\/\/public4.pagefreezer.com\/browse\/FDA\/01-02-2023T10:30\/https:\/www.fda.gov\/media\/107553\/download; 2017 [accessed September 28, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0010","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1136\/annrheumdis-2019-216639","article-title":"Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares","volume":"80","author":"Didierlaurent","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0011","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/annrheumdis-2019-215724","article-title":"Risk of gout flares after vaccination: a prospective case cross-over study","volume":"78","author":"Yokose","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0013","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0014","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0015","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0016","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837632","article-title":"Current approaches to vaccine safety using observational data: a rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) study design","volume":"13","author":"Lai","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0018","unstructured":"Medicare. What Medicare covers, https:\/\/www.medicare.gov\/what-medicare-covers; [accessed March 30, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0019","unstructured":"Medicare. Drug coverage (Part D), https:\/\/www.medicare.gov\/drug-coverage-part-d; [accessed September 13, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/art.22474","article-title":"Validity of gout diagnoses in administrative data","volume":"57","author":"Harrold","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pds.4044","article-title":"Validation of claims-based algorithms for gout flares","volume":"25","author":"MacFarlane","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0022","doi-asserted-by":"crossref","first-page":"R224","DOI":"10.1186\/ar4425","article-title":"Veterans Affairs databases are accurate for gout-related health care utilization: a validation study","volume":"15","author":"Singh","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0023","unstructured":"Gaffo A.L. Treatment of gout flares, https:\/\/www.uptodate.com\/contents\/treatment-of-gout-flares\/print; [accessed May 09, 2024]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0024","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2288-14-122","article-title":"Conditional Poisson models: a flexible alternative to conditional logistic case cross-over analysis","volume":"14","author":"Armstrong","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0027","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or avoidance of medical care because of COVID-19-related concerns - United States","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0028","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0029","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2015.09.087","article-title":"Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females","volume":"34","author":"Yih","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002844","article-title":"Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: a self-controlled risk interval and cohort study with null results","volume":"16","author":"Baker","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0031","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost & Utilization Project. NIS overview, https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp; [accessed March 30, 2023]."},{"key":"10.1016\/j.semarthrit.2024.152515_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0304-4076(81)90071-3","article-title":"Likelihood of a model and information criteria","volume":"16","author":"Akaike","year":"1981","journal-title":"J Econometrics"},{"key":"10.1016\/j.semarthrit.2024.152515_bib0033","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/sim.2477","article-title":"Sample sizes for self-controlled case series studies","volume":"25","author":"Musonda","year":"2006","journal-title":"Stat Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T22:48:26Z","timestamp":1728514106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"alternative-id":["S0049017224001550"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152515","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged \u226565 years","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152515"}}